LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aandelen Lijst・Arvinas Inc

Arvinas Inc

Gesloten

SectorGezondheidszorg

9.08 -3.51

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.86

Max

9.38

Belangrijke statistieken
By Trading Economics
Inkomsten	9.8M -58M
Verkoop	6.1M 16M
EPS	-0.9
Winstmarge	-369.231
Werknemers	246
EBITDA	2.2M -64M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+61.36% upside

Dividenden
By Dow Jones
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-280M 623M
Vorige openingsprijs	12.59
Vorige sluitingsprijs	9.08

Nieuwssentiment

By Acuity

36%

64%

110 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

6.55 / 9.11 Steun & Weerstand

Arvinas Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 mei 2026, 22:47 UTC

Populaire aandelen

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mei 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mei 2026, 22:00 UTC

Belangrijke Marktbewegers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mei 2026, 18:09 UTC

Belangrijke Marktbewegers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 mei 2026, 16:02 UTC

Winsten

Belangrijke Marktbewegers

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 mei 2026, 14:55 UTC

Belangrijke Marktbewegers

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 mei 2026, 14:43 UTC

Belangrijke Marktbewegers

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 mei 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:59 UTC

Acquisities, Fusies, Overnames

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mei 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mei 2026, 21:16 UTC

Marktinformatie

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 20:19 UTC

Populaire aandelen

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mei 2026, 19:41 UTC

Acquisities, Fusies, Overnames

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mei 2026, 19:35 UTC

Marktinformatie

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mei 2026, 18:35 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 mei 2026, 17:28 UTC

Marktinformatie

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 mei 2026, 16:50 UTC

Acquisities, Fusies, Overnames

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 mei 2026, 16:24 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

15 mei 2026, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 15:55 UTC

Marktinformatie

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 mei 2026, 15:20 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 mei 2026, 15:20 UTC

Marktinformatie

Silver Plunges on Inflation Worries -- Market Talk

15 mei 2026, 15:20 UTC

Winsten

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 mei 2026, 14:33 UTC

Marktinformatie

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Peer Vergelijking

Prijswijziging

Arvinas Inc Prognose

Koersdoel

By TipRanks

61.36% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15.2 USD 61.36%

Hoogste 24 USD

Laagste 6 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arvinas Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

17 ratings

Buy

Hold

Sell

Gebaseerd op 17 analisten die aandelenratings hebben gegeven aan Arvinas Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

6.55 / 9.11Steun & Weerstand

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There is one bearish event.

Sentiment

By Acuity

110 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.